Merck KGaA to Acquire Silence Therapeutics
Merck KGaA agreed to acquire Silence Therapeutics in an all-cash transaction valued at approximately $1.3 billion in equity value and $1.1 billion in enterprise value. The proposed deal adds the Phase 3-ready, quarterly siRNA…
